Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Press Release

HPTN 058 HIV Prevention Study Among Injection Drug Users to Close Early

Interim Review Finds Study Cannot Achieve Primary Objectives

October 17, 2011

HPTN 058, a Phase III clinical trial evaluating whether medication combined with drug and HIV risk-reduction counseling can prevent HIV infection and death among opiate-dependent injection drug users, will cease new enrollment and begin a phased close out. The actions are being taken after an independent data and safety monitoring board (DSMB) recently concluded that based on available study data, the trial will be unable to achieve its primary objectives. The DSMB, therefore, recommended that the study end. As the study's sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, agreed with the DSMB's recommendation.

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
Ask Our Expert, David Fawcett, Ph.D., L.C.S.W., About Substance Use and HIV
More News and Research on Injection Drug Use and HIV

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement